TME Pharma
 | |
| Company type | Aktiengesellschaft |
|---|---|
| Founded | 1997 |
| Headquarters | Berlin, Germany |
Key people |
|
Number of employees | 55 (2014)[1] |
| Website | www.noxxon.com |
Noxxon Pharma AG is a small-to-medium-sized company founded in year 1997 in Berlin, Germany and since then is headquartered there. The stocks of the company are not publicly traded. The term Noxxon is a registered trademark[2] and represents a palindrome which reads the same in either forward or reverse direction.
The subject of the company's business is development of drugs. The active ingredients are discovered under a patented technology yielding L-RNA molecules, which are of mirror-image configuration compared to natural occurring D-RNA molecules. This class of agents is termed Spiegelmer,[3][4] which is a registered trademark of Noxxon Pharma AG.[5] The word 'Spiegel' is the German word for 'mirror'. The company is member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller (vfa).
Products
While no Spiegelmer is on the market yet, some candidates are already in clinical trials necessary for approval. Drug candidates for different diseases (indications) are evaluated:
In the area of oncology (cancer) a Spiegelmer is under development for treatment of Multiple myeloma (MM) and Chronic lymphocytic leukemia (CLL).[6][7][8]
A different Spiegelmer is currently being tested for the treatment of a progressive kidney disease in diabetics, Diabetic nephropathy.[9] Favorable results were reported in June, 2014 in a company press release.[10]
A third Spiegelmer is currently in a clinical trial for the treatment of Anemia of chronic disease.[11][12]
References
- ^ Home. Noxxon.com. Retrieved on 2014-12-01.
- ^ DPMAregister
- ^ Vater A, Klussmann S (March 2003). "Toward third-generation aptamers: Spiegelmers and their therapeutic prospects". Curr Opin Drug Discov Devel. 6 (2): 253–61. PMID 12669461.
- ^ Eulberg D; et al. (2006), "Spiegelmers for Therapeutic Applications", The Aptamer Handbook, WILEY-VCH, pp. 417–42, ISBN 3-527-31059-2
{{citation}}:|chapter=ignored (help); Explicit use of et al. in:|author=(help) - ^ DPMAregister
- ^ Vater A, et al. (July 2013). "Hematopoietic Stem and Progenitor Cell Mobilization in Mice and Humans by a First-in-Class Mirror-Image Oligonucleotide Inhibitor of CXCL12". Clin Pharmacol Ther. 94 (1): 150–7. doi:10.1038/clpt.2013.58. PMID 23588307.
- ^ Clinical trial number NCT01521533 for "NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma" at ClinicalTrials.gov
- ^ Clinical trial number NCT01486797 for "NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia" at ClinicalTrials.gov
- ^ Clinical trial number NCT01547897 for "NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria" at ClinicalTrials.gov
- ^ http://www.noxxon.com/downloads/pressrel/2014-06-02_NOXXONs_Emapticap_Pegol_Study_Selected_for_Late_Breaking_Clinical_Trials_Symposium.pdf.
- ^ Clinical trial number NCT01691040 for "Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer" at ClinicalTrials.gov
- ^ Schwoebel F, et al. (March 2013). "The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys". Blood. 121 (12): 2311–5. doi:10.1182/blood-2012-09-456756. PMID 23349391.